# US 2019/0054181 A1 · Fap-activated proteasome inhibitors for treating solid tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0054181 A1
- Document ID: US20190054181A1
- Status: Published application
- Kind: A1
- Application number: 15/952,648
- Filed: 2018-04-13
- Published: 2019-02-21
- Earliest claimed: 2011-08-30
- Assignees: Trustees of Tufts College
- Applicants: Trustees of Tufts College
- Inventors: William W. Bachovchin; Hung-sen Lai; Sarah E. Poplawski
- Web page: https://patentgrep.com/patent/US20190054181A1

## CPC

- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 31/69: Boron compounds
- A61K 38/07: Tetrapeptides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/54: the modifying agent being an organic compound
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/06: Antipsoriatics
- A61P 35/00: Antineoplastic agents
- C07K 5/06026: {the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala}
- C07K 5/06034: {the side chain containing 2 to 4 carbon atoms}
- C07K 5/06078: {and aromatic or cycloaliphatic}
- C07K 5/0806: {the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala}
- C07K 5/0808: {the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu}
- C07K 5/081: {the side chain containing O or S as heteroatoms, e.g. Cys, Ser}
- C07K 5/0812: {and aromatic or cycloaliphatic}
- C07K 5/0821: {with the first amino acid being heterocyclic, e.g. His, Pro, Trp}
- C07K 5/1016: {and aromatic or cycloaliphatic}
- G01N 33/575: for cancer
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed are proteasome inhibitors, fibroblast activation protein (FAP)-activated prodrugs of proteasome inhibitors, and pharmaceutically acceptable salts of the inhibitors and prodrugs. Also disclosed are related pharmaceutical compositions, and methods of using the inhibitors and prodrugs and compositions thereof, for example, in treating cancer or other cell proliferative diseases. In vitro and in vivo methods of quantifying the expression of FAP in a biopsy sample and a mammal, respectively, are also disclosed.

## Claims

### Claim at position 1

1-53. (canceled)

### Claim 54

A method of inhibiting proteasome function in a cell, comprising contacting the cell with an effective amount of a fibroblast activation protein (FAP)-activated proteasome inhibitor represented by formula III:
wherein
R1—(C═O)— represents an acyl N-terminal blocking group;
R2 represents H, lower alkyl, or a mono- or di-hydroxy-substituted lower alkyl;
R3 represents lower alkyl;
R4 is absent;
R5 represents a hydrophobic amino acid sidechain;
R6 represents alkyl, cycloalkyl, aryl, heterocycle or —(CH2)n—R7;
R7 represents aryl, aralkyl, cycloalkyl, alkoxy, alkylthio, —OH or —SH;
R11 represents H or lower alkyl;
W represents
Y1 and Y2 are independently OH, or a group capable of being hydrolyzed to a hydroxyl group; or Y1 and Y2 taken together with the B to which they are attached form a ring having from 5 to 8 atoms in the ring structure; and
n is an integer in the range of 1 to 8.

### Claim at position 3

55-59. (canceled)

### Claim 60

A method of inhibiting antigen presentation in a cell, comprising contacting the cell with an effective amount of a fibroblast activation protein (FAP)-activated proteasome inhibitor represented by formula III:
wherein
R1—(C═O)— represents an acyl N-terminal blocking group;
R2 represents H, lower alkyl, or a mono- or di-hydroxy-substituted lower alkyl;
R3 represents lower alkyl;
R4 is absent;
R5 represents a hydrophobic amino acid sidechain;
R6 represents alkyl, cycloalkyl, aryl, heterocycle or —(CH2)n—R7;
R7 represents aryl, aralkyl, cycloalkyl, alkoxy, alkylthio, —OH or —SH;
R11 represents H or lower alkyl;
W represents
Y1 and Y2 are independently OH, or a group capable of being hydrolyzed to a hydroxyl group; or Y1 and Y2 taken together with the B to which they are attached form a ring having from 5 to 8 atoms in the ring structure; and
n is an integer in the range of 1 to 8.

### Claim at position 5

61-79. (canceled)

### Claim 80

A method of inhibiting HIV infection in a mammal, comprising administering to a mammal in need thereof a therapeutically effective amount of a fibroblast activation protein (FAP)-activated proteasome inhibitor represented by formula III:
wherein
R1—(C═O)— represents an acyl N-terminal blocking group;
R2 represents H, lower alkyl, or a mono- or di-hydroxy-substituted lower alkyl;
R3 represents lower alkyl;
R4 is absent;
R5 represents a hydrophobic amino acid sidechain;
R6 represents alkyl, cycloalkyl, aryl, heterocycle or —(CH2)n—R7;
R7 represents aryl, aralkyl, cycloalkyl, alkoxy, alkylthio, —OH or —SH;
R11 represents H or lower alkyl;
W represents
Y1 and Y2 are independently OH, or a group capable of being hydrolyzed to a hydroxyl group; or Y1 and Y2 taken together with the B to which they are attached form a ring having from 5 to 8 atoms in the ring structure; and
n is an integer in the range of 1 to 8.

### Claim at position 7

81-122. (canceled)

### Claim 123 (depends on 54)

The method of claim 54, wherein R3 is methyl.

### Claim 124 (depends on 54)

The method of claim 54, wherein Y1 and Y2 are OH.

### Claim 125 (depends on 54)

The method of claim 54, wherein R6 is iso-butyl.

### Claim 126 (depends on 54)

The method of claim 54, wherein R11 is H.

### Claim 127 (depends on 54)

The method of claim 54, wherein the FAP-activated proteasome inhibitor is represented by:

### Claim 128 (depends on 60)

The method of claim 60, wherein R3 is methyl.

### Claim 129 (depends on 60)

The method of claim 60, wherein Y1 and Y2 are OH.

### Claim 130 (depends on 60)

The method of claim 60, wherein R6 is iso-butyl.

### Claim 131 (depends on 60)

The method of claim 60, wherein R11 is H.

### Claim 132 (depends on 60)

The method of claim 60, wherein the FAP-activated proteasome inhibitor is represented by:

### Claim 133 (depends on 80)

The method of claim 80, wherein R3 is methyl.

### Claim 134 (depends on 80)

The method of claim 80, wherein Y1 and Y2 are OH.

### Claim 135 (depends on 80)

The method of claim 80, wherein R6 is iso-butyl.

### Claim 136 (depends on 80)

The method of claim 80, wherein R11 is H.

### Claim 137 (depends on 80)

The method of claim 80, wherein the FAP-activated proteasome inhibitor is represented by:
